Captozyme Secures $3.4 Million to Continue Enzyme Research

Wednesday, March 15, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

A resident of the Sid Martin Biotechnology Institute at the University of Florida, Captozyme develops and commercializes innovative enzyme-based solutions that address unmet health needs.

GAINESVILLE, Fla., March 15, 2017 /PRNewswire/ -- Captozyme Inc., a biotechnology company focused on therapeutic

enzyme-based products for health and wellness, recently raised $3.4 million in a Round A. The company plans to invest the funding in the manufacture and launch of Nephure™, an oxalate-degrading enzyme that facilitates a low-oxalate diet.

"We are humbled by the confidence put in us to continue our research and develop products for marketplace introduction," said Aaron Cowley, PhD, Captozyme Co-founder. "Our team remains dedicated to making Captozyme products serve the needs of our most important stakeholders, the people who are currently struggling on a low-oxalate diet."

Mark S. Long, Director of the Sid Martin Biotechnology Institute, commented, "This new funding is additional validation of the significance of Captozyme proprietary research and the company's strong product pipeline in the medical foods and orphan drug markets."

Nephure Pre-Clinical Data

The goal of Nephure is to make being healthier and following a low-oxalate diet easier.  Normal consumption of calcium is useful in normalizing relatively high urinary oxalate. Sticking to a low-oxalate diet can be challenging, especially when there can be a wide range of discrepancies online about what food is generally considered oxalate-rich. Nephure takes away this uncertainty by breaking down the oxalate compound in food.

A low-oxalate diet should limit oxalate intake to 40-50 mg daily, although in the U.S. oxalate intake is estimated to average 150-200 mg every day.

Captozyme's pre-clinical data of Nephure features:

  • 40-60% reduction in urinary oxalate when administered to an animal model with high urinary oxalate
  • successful creation of oxalate-free craft beer and ready-to-drink tea and juices

Developed from years of rigorous scientific research, Nephure is a safe, effective solution that aids a low-oxalate diet by breaking down the oxalate and increasing the food's nutritional value.

About Captozyme, Inc.

Captozyme, Inc. is a biotechnology company dedicated to helping people better manage their diets and overall health. The company plans to launch Nephure in the spring of 2017. With Nephure the company has created a product that allows people to enjoy the foods they love without the consequences of adding oxalate to their bodies. Learn more about Captozyme at or visit

Interested in receiving more information on Nephure? Follow Nephure on Facebook, Twitter or sign up for the newsletter.

About Sid Martin Biotechnology Institute at the University of Florida

The Sid Martin Biotechnology Institute is the leading biotechnology incubator headquartered at the University of Florida in Alachua, Florida at Progress Park. The Institute has been honored with national and international awards for incubator excellence and achievements in technology commercialization, funding access, job creation and technology-based economic development. It is dedicated to mentoring and accelerating the growth of innovative early-stage bioscience and biotechnology companies, and supporting the economic growth of the North Central Florida region.  For more information, visit.


Aaron CowleyCo-founderCaptozyme Inc.                                                                                                                                785.760.3128                                                                    

Merrie ShawAssistant DirectorSid Martin Biotechnology Institute386-462-0880

This content was issued through the press release distribution service at For more info visit:

To view the original version on PR Newswire, visit:

SOURCE Captozyme


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store